Abstract
Background: VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro. Methods: A randomised, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacodynamics of VX-809 in adult patients with cystic fibrosis (n=89) who were homozygous for the F508del-CFTR mutation. Subjects were randomised to one of four VX-809 28 day dose groups (25, 50, 100 and 200 mg) or matching placebo. Results: The type and incidence of adverse events were similar among VX-809- and placebo-treated subjects. Respiratory events were the most commonly reported and led to discontinuation by one subject in each active treatment arm. Pharmacokinetic data supported a once-daily oral dosing regimen. Pharmacodynamic data suggested that VX-809 improved CFTR function in at least one organ (sweat gland). VX-809 reduced elevated sweat chloride values in a dose-dependent manner (p=0.0013) that was statistically significant in the 100 and 200 mg dose groups. There was no statistically significant improvement in CFTR function in the nasal epithelium as measured by nasal potential difference, nor were there statistically significant changes in lung function or patient-reported outcomes. No maturation of immature F508del-CFTR was detected in the subgroup that provided rectal biopsy specimens. Conclusions: In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland. Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. Clinical trial number: NCT00865904.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 12-18 |
| Number of pages | 7 |
| Journal | Thorax |
| Volume | 67 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2012 |
Bibliographical note
Funding Information:Funding Supported by Vertex Pharmaceuticals and grants CTSA UL1 RR024134 to the Children's Hospital of Philadelphia; NIH 1UL1 RR025744 to Stanford University; NIH K23 DK075788 to SMR; IUL1 RR025777 to Dr Guay-Woodford; CFF CLANCY09YO to SMR; AMIN09YO to RSA; NIH/NCRR/CTSA Grant UL1 RR024153 to the University of Pittsburgh; UL1 RR024992 from the National Center for Research Resources (NCRR) , a component of the NIH, and NIH Roadmap for Medical Research; NIH grants UL1 RR024989 and P30 DK27651 to Case Western Reserve University; UL1 RR025747 from the NCRR . M01 RR00400 from the NCRR from Harvard Catalyst/The Harvard Clinical and Translational Science Center (NIH Award #UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centres) . UL1 RR 025005 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research to the Johns Hopkins School of Medicine . CTSA (Clinical and Translational Science Award) Grant number is 1UL1 RR025014 to the University of Washington. CFFT Durie 06A0. CTSA grant: UL1RR025747 to the University of North Carolina Chapel Hill. CTSA 1UL1 RR025780 to University of Colorado. Washington University ICTS/CTSA Grant Number UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research to Washington University in St. Louis. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centres, the NCRR or the NIH.
